F10 and cancer: In the sensitivity analysis with 9 years of follow-up, cancer incidence was significantly lower in the factor Xa inhibitor group than in the dabigatran group (2,277/23,711 (9.60%) versus 2,706/23,715 (11.41%); SHR 0.88, 95% CI [0.83,0.93]) (S6 Table).